Clinical trial · Observational
Breath Test to Predict Breast Cancer and Outcome of Mammography
NCT04755829CI-TRIAL-00050087unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To validate a breath test that predicts risk of breast cancer and an abnormal mammogram.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abnormal Mammogram, Unspecified | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BreathX test for breath VOCs | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group 1
- description
- Normal screening mammogram (BIRADS 1 or 2)
- interventionNames
- Device: BreathX test for breath VOCs
- label
- Group 2
- description
- Abnormal screening mammogram (BIRADS 3 to 6)
- interventionNames
- Device: BreathX test for breath VOCs
Primary outcomes (2)
- measure
- BREATH TEST TO PREDICT BREAST CANCER
- timeFrame
- 2 years
- description
- Determination of the sensitivity, specificity, and positive and negative predictive values of a breath test for biomarkers that predict the risk of an abnormal mammogram.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Group 1: Normal screening mammogram Inclusion Criteria: 1. Female aged 18 years or older 2. Understands the study, and is willing to give written informed consent to participate 3. If a screening mammogram was performed during the preceding six month period, then the results were reported as normal (BIRADS 1 or 2) 4. If a screening mammogram was not performed during the preceding six month period, then approves collection of the results of a screening mammogram if and when it is performed subsequently\*. 5. Approves collection of relevant additional data for clinical research record if and when these data become available, including results of imaging studies, breast biopsy, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-) \* If a subsequent screening mammogram is reported as abnormal, the subject will be transferred to Group 2 for analysis of data. Exclusion Criteria: 1. Previous history of an abnormal mammogram, breast disease, or breast biopsy 2. Previous history of cancer of any site, with the exception of basal cell carcinoma of skin 3. Concurrent serious or potentially life-threatening disease (e.g. severe cardiac or infectious disease) 4. Concurrent acute pulmonary disease (e.g. influenza, influenza-like illness, acute asthma, or pneumonitis). 5. General anesthesia during the 10-day period prior to breath collection. Group 2: Abnormal screening mammogram Inclusion Criteria: Female aged 18 years or older 1. Understands the study, and is willing to give written informed consent to participate 2. Abnormal screening mammogram during preceding six months (BIRADS 3-6) 3. Approves collection of relevant additional data for clinical research record if and when it becomes available, including results of imaging studies, biopsy results, and other relevant biomarker data e.g. status of BRCA1, BRCA2, HER2 and receptors (ER+ or ER-) and progesterone (PgR+ or PgR-) Exclusion criteria: 1. Previous history of cancer of any site, with the exception of basal cell carcinoma of skin 2. Previous history of breast biopsy 3. Concurrent serious or potentially life-threatening disease (e.g. severe cardiac or infectious disease) 4. Concurrent acute pulmonary disease (e.g. influenza, influenza-like illness, acute asthma, or pneumonitis). 5. General anesthesia during the 10-day period prior to breath collection. -
References
Publications (37)
- BACKGROUNDSmith-Bindman R, Chu PW, Miglioretti DL, Sickles EA, Blanks R, Ballard-Barbash R, Bobo JK, Lee NC, Wallis MG, Patnick J, Kerlikowske K. Comparison of screening mammography in the United States and the United kingdom. JAMA. 2003 Oct 22;290(16):2129-37. doi: 10.1001/jama.290.16.2129. PMID 14570948
- BACKGROUNDHealth, United States, 2015. Centers for Disease Control and Prevention National Center for Health Statistics; 2015.
- BACKGROUNDJiang Y, Miglioretti DL, Metz CE, Schmidt RA. Breast cancer detection rate: designing imaging trials to demonstrate improvements. Radiology. 2007 May;243(2):360-7. doi: 10.1148/radiol.2432060253. PMID 17456866
- BACKGROUNDWhite A, Miller J, Royalty J, Ryerson AB, Benard V, Helsel W, Kammerer W. Clinical outcomes of mammography in the National Breast and Cervical Cancer Early Detection Program, 2009-2012. Cancer Causes Control. 2015 May;26(5):723-32. doi: 10.1007/s10552-015-0567-7. Epub 2015 Mar 26. PMID 25809209
- BACKGROUNDWelch HG, Passow HJ. Quantifying the benefits and harms of screening mammography. JAMA Intern Med. 2014 Mar;174(3):448-54. doi: 10.1001/jamainternmed.2013.13635. PMID 24380095
- BACKGROUNDHackshaw A. Benefits and harms of mammography screening. BMJ. 2012 Jan 6;344:d8279. doi: 10.1136/bmj.d8279. No abstract available. PMID 22228697
- BACKGROUNDKneepkens CM, Ferreira C, Lepage G, Roy CC. The hydrocarbon breath test in the study of lipid peroxidation: principles and practice. Clin Invest Med. 1992 Apr;15(2):163-86. PMID 1591898
- BACKGROUNDKneepkens CM, Lepage G, Roy CC. The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med. 1994 Aug;17(2):127-60. doi: 10.1016/0891-5849(94)90110-4.